Q4 EARNINGS: Danaher in line, but Philips’ dismal run continues
This article was originally published in Clinica
Danaher’s fourth-quarter sales of $5.42bn and adjusted earnings of $1.04 per share came in just ahead of analyst consensus of $5.39bn and $1.03 per share, respectively. Q4 sales were up 3% year-on-year, while core revenues increased 4%; this beat consensus analyst prediction of 2.8% growth and the best result since Q4 2011, according to Jefferies analyst Brandon Couillard. “The upside came from better T&M [test & measurement], environmental and industrial trends,” he added.